Pretreatment obesity prolongs survival in elderly patients (≥65 years) with head and neck cancer (HNC).

Authors

null

Parth Anil Desai

UT Health San Antonio, San Antonio, TX

Parth Anil Desai , Sushanth Kakarla , Annapurna Saksena , Byeongyeob Choi , Martin Goros , Frank R. Miller , Anand B. Karnad , Sherri Rauenzahn Cervantez

Organizations

UT Health San Antonio, San Antonio, TX, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX

Research Funding

Other

Background: Pre-treatment Body mass Index (BMI) is an important prognostic factor in HNC with variable survival benefit reported till date. Despite increasing incidence of HNC in geriatric patients there is limited information on prognostic variables in this group. Methods: This is a single center, retrospective cohort study of patients with HNC≥65 years of age at their diagnosis from 2012 to 2016. Patients were stratified by BMI (Class 1- BMI<25 kg/m2 (underweight & normal), Class 2- BMI≥25-29.9 kg/m2 (overweight), Class 3- BMI≥30 kg/m2 (obese) ). Various variables were collected & appropriate statistical analysis was done. Results: 188 elderly HNC patients with non-metastatic disease were stratified into three BMI groups (Table) & found to have evenly distributed co-variates. The Median OS was significantly higher in class 3 patients (53 months) compared to class 1 (21 months) (p =0.02). In multivariate analysis, class 3 was an independent good prognostic indicator (Hazard ratio=0.44;Range-0.21-0.90, p=0.03). Stage, CCI score & gastrostomy tube were adverse prognostic factors in the study. Conclusions: Obese elderly HNC patients have survival benefit over normal/underweight patients. Predictive prognostic models incorporating BMI with other prognostic factors are needed to determine appropriate management in these patients.

CHARACTERISTICSClass 1
BMI <25
(78 patients)
Class 2
BMI 25-29.9
(67 patients)
Class 3
BMI ≥ 30
(43 patients)
p-value
MEAN AGE AT DIAGNOSIS (SD) Years75.12 (7.46)73.38 (6.13)73.96 (6.14)0.290
SEX (%)
WOMEN27 (34.6)16 (23.9)15 (34.9)0.305
MEN51 (65.4)51 (76.1)28 (65.1)
PATHOLOGICAL TYPE (%)
SCC71 (90.9)58 (86.6)36 (83.7)0.409
OTHERS8 (9.1)9 (13.4)7 (16.2)
TNM STAGE (%)
STAGE 15 (6.4)11 (16.4)8 (18.6)0.745
STAGE 213 (16.7)9 (13.4)9 (20.9)
STAGE 39 (11.5)7 (10.4)4 (9.3)
STAGE 4A34 (43.6)24 (35.8)13 (31.0)
STAGE 4B12 (15.3)11 (16.0)5 (11.6)
UNKNOWN5 (6.4)5 (7.5)4 (9.3)
CHARLSON COMORBIDITY INDEX (CCI) MEAN (SD)
INITIAL TREATMENT (%)5.03 (2.34)5.54 (2.92)5.28 (1.78)0.460
CHEMOTHERAPY ONLY5 (6.4)1 (1.5)2 (4.7)0.628
CHEMOTHERAPY + SURGERY0 (0.0)0 (0.0)1 (2.3)
CHEMORADIATION16 (20.5)13 (19.4)8 (18.6)
CHEMORADIATION + SURGERY6 (7.7)10 (14.9)5 (11.6)
RADIATION ONLY7 (9.0)9 (13.4)7 (16.3)
RADIATION +SURGERY8 (10.3)10 (14.9)7 (16.3)
SURGERY ONLY19 (24.4)14 (20.9)7 (16.3)
NONE/SUPPORTIVE ONLY/HOSPICE17 (21.8)10 (14.9)6 (14.0)
MEAN SURVIVAL TIME (SD) Days368.35 (353.9)527.08 (319.10)590.27 (495.62)0.080
DECEASED AT LAST FOLLOW-UP (%)
NO35 (44.9)42 (62.7)28 (65.1)0.037
YES43 (55.1)25 (37.3)15 (34.9)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Biologic Correlates

Citation

J Clin Oncol 37, 2019 (suppl; abstr 6052)

DOI

10.1200/JCO.2019.37.15_suppl.6052

Abstract #

6052

Poster Bd #

41

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Prognostic factors for GEM + nab-PTX combination therapy in elderly patients with pancreatic cancer.

First Author: Kazuki Watabe

First Author: Sakditad Saowapa

First Author: Anshu Hemrajani